Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 195-198

  Markman, Maurie ^a   Liu, P Y ^b   Moon, James ^b   Monk, Bradley J ^c   Copeland, Larry ^d   Wilczynski, Sharon ^e   Alberts, David ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Advanced ovarian cancer; Chemotherapy; Maintenance chemotherapy; Phase 3 trial

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG TOXICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS;

EID: 67549104877     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.012     Document Type: Article

References (15)

1. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
2. Rowinsky E.K., and Donehower R.C. Paclitaxel (taxol). N. Engl. J. Med. 332 (1995) 1004-1014
3. Rowinsky E.K., Donehower R.C., Jones R.J., and Tucker R.W. . Microtubule changes and cytotoxicity in leukemia cell lines treated with taxol. Cancer Res. 48 (1988) 4093-4100
4. Lopes N.M., Adams E.G., Pitts T.W., and Bhuyan B.K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32 (1993) 235-242
5. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878-1886
6. Markman M., Hakes T., Barakat R., Curtin J., Almadrones L., and Hoskins W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103:Paclitaxel in refractory ovarian cancer. J. Clin. Oncol. 14 (1996) 796-799
7. von Gruenigen V.E., Karlen J.R., and Waggoner S.E. A case of chronic paclitaxel administration in ovarian cancer. Gynecol. Oncol. 89 (2003) 532-535
8. Rohl J., Kushner D., and Markman M. Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol. Oncol. 81 (2001) 201-205
9. Markman M., Liu P.Y., Rothenberg M.L., Monk B.J., Brady M., and Alberts D.S. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J. Clin. Oncol. 24 (2006) 1454-1458
10. Hakes T.B., Chalas E., Hoskins W.J., Jones W.B., Markman M., and Rubin S.C. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol. Oncol. 45 (1992) 284-289
11. Bertelsen K., Jakobsen A., Stroyer J., Nielsen K., Sandberg E., Andersen J.E., et al. A prospective randomized comparison of 6 and 12 courses of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol.Oncol. 49 (1993) 30-36
12. Lambert H.E., Rustin G.J.S., Gregory W.M., and Nelstrop A.E. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. Ann. Oncol. 8 (1997) 327-333
13. Bozcuk H., Artac M., Ozdogan M., and Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer?. Cancer 104 (2005) 2650-2657
14. DePlacido S., Scambia G., DiVagno G., Naglieri E., Lombardi A.V., Biamonte R., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol. 22 (2004) 2635-2642
15. Conte P.F., Favalli G., Gadducci A., Katsaros D., Benedetti Panici P.L., Carpi A., et al. Final results of After-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy. J. Clin. Oncol. 25 18 suppl (2007) 275s (abstract 5505)